Nestle Likely In Lead To Buy Pfizer's $10B Baby Food Line

Law360, New York (February 24, 2012, 5:04 PM EST) -- Swiss food giant Nestle SA is the favorite to buy Pfizer Inc.'s infant nutrition business, which could be worth $10 billion, an analyst said Thursday, partly because another leading bidder, France's Danone SA, could face an antitrust challenge in China.

It was about one year ago that New York-based Pfizer — the world's biggest pharmaceutical company — first announced a plan to sell off noncore assets, among them its baby food business, whose profits come from overseas. Pfizer picked up the operations in its 2009 acquisition of Wyeth...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.